[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Dr. Md. Alimur Reza\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":95},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,40,68],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":5},"100600611","effectiveness-and-safety-of-tirzepatide-among-participants-with-obesity-with-or-without-type-2-diabetes-mellitus-t2dm-100600611",false,"NCT07099742","Effectiveness and Safety of Tirzepatide Among Participants With Obesity With or Without Type 2 Diabetes Mellitus (T2DM)","A Study of Real-World Effectiveness and Safety of Tirzepatide Among Participants With Obesity With or Without Type 2 Diabetes Mellitus (T2DM) in Bangladesh","Inclusion Criteria:\n\n* Adult patients of both sexes, aged ≥18 years.\n* Body mass index (BMI) ≥25 kg\u002Fm².\n* Naïve to glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy.\n* Self-reported stable body weight (change ≤5 kg) over the past 3 months.\n\nExclusion Criteria:\n\n* Diagnosis of diabetes other than Type 2 Diabetes Mellitus.\n* History of chronic or acute pancreatitis.\n* Presence of acute medical conditions, including acute hepatitis, myocardial infarction, stroke, heart failure, febrile illness, or acute diarrheal disease.\n* Evidence of significant, uncontrolled endocrine disorders (e.g., Cushing's syndrome, thyroid disorders, adrenal insufficiency, congenital adrenal hyperplasia).\n* History or presence of malignancy.\n* Active gallbladder disease.\n* Female participants who are pregnant, breastfeeding, planning pregnancy, or of childbearing potential, not using adequate contraceptive methods.\n* Prior or planned surgical treatment for obesity.\n* Use of weight-loss products (including prescription medications, over-the-counter drugs, or herbal preparations) within 3 months prior to screening.","ALL","18 Years",{"count":19,"type":20},364,"ESTIMATED","OBSERVATIONAL","This is a prospective, multicenter, real-world study conducted in Bangladesh to assess the effectiveness and safety of Tirzepatide compared to structured lifestyle interventions, including dietary modifications and exercise, in obese adults with or without Type 2 Diabetes Mellitus (T2DM).\n\nThe study aims to determine whether treatment with Tirzepatide results in superior weight reduction outcomes compared to lifestyle-based approaches. Adult participants (≥18 years) with a body mass index (BMI) ≥25 kg\u002Fm² and no prior exposure to GLP-1 receptor agonists will be enrolled at the discretion of the treating physician. Eligible participants will receive either once-weekly Tirzepatide or participate in lifestyle intervention programs aligned with standard clinical care.",[24],"Obesity",[26,24,27],"Tirzepatide","T2DM","NOT_YET_RECRUITING","2025-07-31",{"date":31,"type":32},"2025-08-03","ACTUAL",{"date":34,"type":20},"2025-09",{"date":36,"type":20},"2026-07",{"name":38,"class":39},"Dr. Md. Alimur Reza","INDUSTRY",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":48,"phases":49,"briefSummary":51,"conditions":52,"keywords":54,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},"100576756","phase-4-efficacy-and-safety-of-atorvastatin-and-ezetimibe-1010mg-fixed-dose-combination-versus-atorvastatin-20mg-monotherapy-in-bangladeshi-population-100576756","NCT06789432","Efficacy and Safety of Atorvastatin and Ezetimibe (10\u002F10mg) Fixed Dose Combination Versus Atorvastatin (20mg) Monotherapy in Bangladeshi Population","Inclusion Criteria:\n\n* Men and women aged \\>18 years.\n* Patients with a confirmed diagnosis of elevated LDL-C levels necessitating medical management.\n* Patients in the low to moderate cardiovascular disease (CVD) risk category according to ESC guidelines (2019)\n\n  * Low-risk: Increased LDL-C level without any co-morbidities\n  * Moderate-risk: Young patients (T1DM \\\u003C35 years; T2DM \\\u003C50 years) with DM duration \\\u003C10 years, without other risk factors.\n\nExclusion Criteria:\n\n* History of hypersensitivity to any study drugs.\n* Clinically significant hepatic impairment (ALT, AST level \\> 2xULN) and\u002For renal impairment (Serum creatinine level ≥2xULN).\n* Patients with hepatitis B virus (HBV) or hepatitis C virus (HCV) with cirrhosis, end-stage liver disease, cancer, psychiatric instability, HIV + status, intestinal malabsorption.\n* Pregnant or lactating females.\n* The presence of a condition that, in the opinion of the investigator, would place the subject at increased risk from study participation.",{"count":47,"type":20},500,"INTERVENTIONAL",[50],"PHASE4","The goal of this clinical trial is to evaluate the efficacy and safety of a fixed-dose combination of atorvastatin (10 mg) and ezetimibe (10 mg) compared to atorvastatin (20 mg) monotherapy in the Bangladeshi population.\n\nResearchers will compare atorvastatin (10 mg) and ezetimibe (10 mg) to atorvastatin (20 mg) monotherapy to see if atorvastatin (10 mg) and ezetimibe (10 mg) FDC works to treat dyslipidemia.\n\nParticipants will:\n\n* Take a fixed-dose combination of atorvastatin (10 mg) and ezetimibe (10 mg) compared to atorvastatin (20 mg) monotherapy for 3 months\n* Follow-up visits at 6 weeks and 12 weeks for checkups and tests",[53],"Hyperlipidemia (E.G., Hypercholesterolemia)",[55,56,57],"increased LDL-C level","Hyperlipidemia","Atorvastatin (10 mg) and Ezetimibe (10 mg)","RECRUITING","2025-07-25",{"date":61,"type":32},"2025-07-29",{"date":63,"type":32},"2025-02-01",{"date":65,"type":20},"2025-12",{"name":38,"class":39},1,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":48,"phases":78,"briefSummary":79,"conditions":80,"keywords":83,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},"100577884","phase-4-efficacy-and-safety-of-faropenem-in-bangladeshi-adult-patients-with-community-acquired-bacterial-pneumonia-cabp-100577884","NCT06804096","Efficacy and Safety of Faropenem in Bangladeshi Adult Patients With Community-Acquired Bacterial Pneumonia (CABP)","Efficacy and Safety of Faropenem in Bangladeshi Adult Patients With Community-Acquired Bacterial Pneumonia (CABP): A Randomized Controlled Trial","Inclusion Criteria:\n\n* Male or female patients aged between 18 to 65 years.\n* Have an acute illness (less than or equal to 7 days duration) with any of the following signs and symptoms consistent with a lower respiratory tract infection (new or worsening):\n\n  1. Fever (body temperature \\> 38.0 °C (100.4 °F) measured orally)\n  2. Shortness of breath\n  3. New onset or increased cough with or without sputum production.\n  4. Chest pain.\n* Have radiographically documented bacterial pneumonia:\n\n  1. Infiltrates in a unilateral, lobar distribution\n  2. Diffuse opacities or white condensed area\n  3. The alveoli fill with white inflammatory fluid\n\nExclusion Criteria:\n\n* Patients with severe pneumonia (Clinical \\& Radiological Assessment)\n* Patients with suspicion of viral pneumonia (bilateral, patchy opacities, etc., in chest radiography.)\n* Patients with suspicion of nosocomial pneumonia, aspiration pneumonia, etc.\n* History of hypersensitivity, known or suspected contraindications, or intolerance to any of the study drugs.\n* Intake of an antibiotic within the last 48 hours before study admission.\n* History of hospitalization within the last 28 days.\n* Patients in pregnancy and lactational state.\n* Patients with Renal impairment (screening eGFR \\\u003C 30mL\u002Fmin).\n* Significant hepatic impairment (Alanine aminotransferase \\> three times the upper limit of normal).\n* Serious diseases that affect the immune system, such as Acquired Immunodeficiency Syndrome (AIDS), cancer, etc.\n* Patients who are taking steroid medications, at least 20 mg daily dose of prednisolone (or equivalent doses of other glucocorticoids).\n* Patients who are accepting chemotherapy or anti-cancer therapy or plan to receive such treatment during the trial or six months prior to enrollment.\n* Had epilepsy, stroke, or other central nervous system disorders or uncontrolled psychiatric history.","65 Years",{"count":77,"type":20},160,[50],"The goal of this clinical trial is to evaluate the efficacy and safety of faropenem in comparison to co-amoxiclav and clarithromycin in Bangladeshi adults diagnosed with community-acquired bacterial pneumonia (CABP). Eligible participants will be randomly assigned to one of two treatment arms. The first arm will receive faropenem at a dosage of 200 mg administered three times daily for a duration of seven days. The second arm will receive co-amoxiclav 625 mg, also three times daily, along with clarithromycin 500 mg, administered twice daily for seven days. All participants included in the study will undergo follow-up assessments over a period of four weeks. This research aims to provide valuable insights regarding the potential role of faropenem, thereby enhancing clinical outcomes and informing antibiotic stewardship in a region significantly burdened by CABP and characterized by limited treatment alternatives.",[81,82],"Pneumonia, Community-Acquired","Bacterial Pneumonia",[84,85],"CABP","Faropenem","2025-07-09",{"date":88,"type":32},"2025-07-11",{"date":90,"type":32},"2025-02-20",{"date":92,"type":20},"2025-12-01",{"name":38,"class":39},2,""]